Breast Cancer | Dissecting the Decision: Optimizing the Use of CDK4/6 Inhibitors in the Management of ER-Positive, HER2-Negative Metastatic Breast Cancer

published 2 months ago by Dr Neil Love

  A roundtable discussion with Drs Neelima Denduluri, Shom Goel, Erika Hamilton, Komal Jhaveri, Ruth M O’Regan and Sara M Tolaney featuring review of patterns of care survey results, presentation of relevant data sets and moderated panel discussion. Module 1: Biology of the CDK4/6 Pathway and Pharmacology of the CDK4/6 Inhibitors Abemaciclib, Ribociclib and Palbociclib General medical oncologist survey results (0:00) Presentation of relevant data sets — Dr Goel (2:27) Panel discussion (11:02) Module 2: Management of ER-Positive, HER2-Negative Metastatic Breast Cancer (mBC) in Postmenopausal Patients General medical oncologist survey results (17:17) Presentation of relevant data sets — Dr Denduluri (18:54) Panel discussion (21:53) Module 3: Role of CDK4/6 Inhibitors for Premenopausal Patients with ER-Positive, HER2-Negative mBC General medical oncologist survey results (30:38) Presentation of relevant data sets — Dr Jhaveri (31:31) Panel discussion (41:59) Module 4: Site and Extent of Metastases, Including CNS Involvement, and Outcomes with CDK4/6 Inhibitors; Predictors of Response to Therapy General medical oncologist survey results (1:5:57) Presentation of relevant data sets — Dr Tolaney (1:7:28) Panel discussion (1:19:33) Module 5: Pathophysiology of Class- and Agent-Specific Toxicities and Optimal Management Strategies General medical oncologist survey results (1:37:04) Presentation of relevant data sets — Dr Hamilton (1:38:12) Panel discussion (1:52:15) Module 6: Mechanisms of Resistance to CDK4/6 Inhibitors, Treatment Beyond Disease Progression and Novel Strategies with Combinations General medical oncologist survey results (2:00:03) Presentation of relevant data sets — Dr O’Regan (2:01:39) Panel discussion (2:06:26) Select publications  

more episodes from Research To Practice | Oncology Videos